Matthew F Mescher
Overview
Explore the profile of Matthew F Mescher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
2458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tucker C, Mitchell J, Martinov T, Burbach B, Beura L, Wilson J, et al.
J Immunol
. 2020 Aug;
205(5):1449-1460.
PMID: 32737148
Optimal ex vivo expansion protocols of tumor-specific T cells followed by adoptive cell therapy must yield T cells able to home to tumors and effectively kill them. Our previous study...
2.
Anderson K, Snyder K, Ito D, Lins D, Mills L, Weiskopf K, et al.
Melanoma Res
. 2019 Jun;
30(2):147-158.
PMID: 31205227
Therapeutic activation of macrophage phagocytosis has the ability to restrain tumour growth through phagocytic clearance of tumour cells and activation of the adaptive immune response. Our objective for this study...
3.
Zumwalde N, Domae E, Mescher M, Shimizu Y
J Immunol
. 2013 Sep;
191(7):3681-93.
PMID: 23997225
A hallmark of T cell activation in vitro and in vivo is the clustering of T cells with each other via interaction of the LFA-1 integrin with ICAM-1. The functional...
4.
Wang Y, Shaked I, Stanford S, Zhou W, Curtsinger J, Mikulski Z, et al.
Immunity
. 2013 Jul;
39(1):111-22.
PMID: 23871208
Immune cells sense microbial products through Toll-like receptors (TLR), which trigger host defense responses including type 1 interferons (IFNs) secretion. A coding polymorphism in the protein tyrosine phosphatase nonreceptor type...
5.
Gerner M, Heltemes-Harris L, Fife B, Mescher M
J Immunol
. 2013 Jun;
191(3):1011-5.
PMID: 23804712
Naive CD8 T cells proliferate in response to TCR and CD28 signals, but require IL-12 or type I IFN to survive and develop optimal effector functions. Although murine CTL generated...
6.
Curtsinger J, Agarwal P, Lins D, Mescher M
J Immunol
. 2012 Jun;
189(2):659-68.
PMID: 22706089
Autocrine IFN-γ signaling is important for CD4 differentiation to Th1 effector cells, but it has been unclear whether it contributes to CD8 T cell differentiation. We show in this paper...
7.
Dings R, Vang K, Castermans K, Popescu F, Zhang Y, Oude Egbrink M, et al.
Clin Cancer Res
. 2011 Jan;
17(10):3134-45.
PMID: 21252159
Purpose: Tumor-released proangiogenic factors suppress endothelial adhesion molecule (EAM) expression and prevent leukocyte extravasation into the tumor. This is one reason why immunotherapy has met with limited success in the...
8.
Curtsinger J, Mescher M
Curr Opin Immunol
. 2010 Apr;
22(3):333-40.
PMID: 20363604
CD8 T cells require a third signal, along with Ag and costimulation, to make a productive response and avoid death and/or tolerance induction. Recent studies indicate that IL-12 and Type...
9.
Agarwal P, Raghavan A, Nandiwada S, Curtsinger J, Bohjanen P, Mueller D, et al.
J Immunol
. 2009 Jul;
183(3):1695-704.
PMID: 19592655
A third signal that can be provided by IL-12 or type I IFN is required for differentiation of naive CD8 T cells responding to Ag and costimulation. The cytokines program...
10.
Xiao Z, Casey K, Jameson S, Curtsinger J, Mescher M
J Immunol
. 2009 Feb;
182(5):2786-94.
PMID: 19234173
Inflammation can have both positive and negative effects on development of CD8 T cell memory, but the relative contributions and cellular targets of the cytokines involved are unclear. Using CD8...